TW200942527A - Pyridazine derivatives as factor XIa inhibitors - Google Patents
Pyridazine derivatives as factor XIa inhibitorsInfo
- Publication number
- TW200942527A TW200942527A TW098108304A TW98108304A TW200942527A TW 200942527 A TW200942527 A TW 200942527A TW 098108304 A TW098108304 A TW 098108304A TW 98108304 A TW98108304 A TW 98108304A TW 200942527 A TW200942527 A TW 200942527A
- Authority
- TW
- Taiwan
- Prior art keywords
- factor xia
- xia inhibitors
- compounds
- pyridazine derivatives
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3612708P | 2008-03-13 | 2008-03-13 | |
| US14520309P | 2009-01-16 | 2009-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200942527A true TW200942527A (en) | 2009-10-16 |
Family
ID=40640383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098108304A TW200942527A (en) | 2008-03-13 | 2009-03-13 | Pyridazine derivatives as factor XIa inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8324199B2 (zh) |
| EP (1) | EP2265601B1 (zh) |
| JP (1) | JP5537442B2 (zh) |
| CN (1) | CN102026996B (zh) |
| AT (1) | ATE543811T1 (zh) |
| ES (1) | ES2380648T3 (zh) |
| TW (1) | TW200942527A (zh) |
| WO (1) | WO2009114677A1 (zh) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791792B2 (en) * | 2010-01-15 | 2014-07-29 | Idex Asa | Electronic imager using an impedance sensor grid array mounted on or about a switch and method of making |
| PH12012501589A1 (en) | 2010-02-11 | 2012-10-22 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| LV14606B (lv) | 2011-05-17 | 2013-01-20 | Tetra, Sia | Jauns XII faktora inhibitors |
| PT2729448E (pt) * | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| HRP20170784T8 (hr) | 2011-10-14 | 2018-05-18 | Bristol-Myers Squibb Company | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| JP6137193B2 (ja) * | 2011-12-21 | 2017-05-31 | 小野薬品工業株式会社 | 第ＸＩａ因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体 |
| JP2015512431A (ja) | 2012-04-04 | 2015-04-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｇｐｂａｒ１モジュレーターとしての１，２−ピリダジン、１，６−ピリダジン又はピリミジン−ベンズアミド誘導体 |
| EP2958053A1 (en) | 2012-04-10 | 2015-12-23 | Idex Asa | Biometric sensing |
| GB201209138D0 (en) * | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| CN104507924B (zh) | 2012-08-03 | 2018-01-23 | 百时美施贵宝公司 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
| WO2014022766A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| HRP20180465T1 (hr) * | 2012-10-12 | 2018-05-04 | Bristol-Myers Squibb Company | Kristalni oblici inhibitora faktora xia |
| US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| US20160257668A1 (en) * | 2013-10-07 | 2016-09-08 | Merck Sharp & Dohme Corp. | Factor XIa Inhibitors |
| UY35971A (es) | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| NO2760821T3 (zh) | 2014-01-31 | 2018-03-10 | ||
| JP6382997B2 (ja) * | 2014-02-07 | 2018-08-29 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
| EP3104703B1 (en) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| US10093683B2 (en) | 2014-04-22 | 2018-10-09 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| EP3180317B1 (en) | 2014-07-28 | 2021-04-14 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| SG10201805646WA (en) | 2014-08-07 | 2018-08-30 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CN104387376B (zh) * | 2014-10-30 | 2017-01-18 | 广东东阳光药业有限公司 | 吡啶酮类化合物及其组合物和用途 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| ES2762987T3 (es) | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| CN114874222B (zh) * | 2015-07-29 | 2025-06-06 | 百时美施贵宝公司 | 携带非芳族p2,基团的因子xia新大环 |
| EP3328851B1 (en) | 2015-07-29 | 2020-04-22 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties |
| US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| CN108430471B (zh) | 2015-10-29 | 2021-07-09 | 默沙东公司 | 因子XIa抑制剂 |
| CN105400143B (zh) * | 2015-12-11 | 2017-10-03 | 广州欣凯化工科技有限公司 | 一种木制品缝隙的修补组合物 |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| HRP20201131T1 (hr) | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| JP6716785B2 (ja) | 2016-08-19 | 2020-07-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| TW201808908A (zh) | 2016-08-22 | 2018-03-16 | 美商默沙東藥廠 | 因子XIa抑制劑 |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| PL3752496T3 (pl) | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| EP3941475A4 (en) * | 2019-03-20 | 2023-01-25 | Goldfinch Bio, Inc. | PYRIDAZINONES AND METHODS OF USE THEREOF |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| WO2021136390A1 (zh) * | 2019-12-31 | 2021-07-08 | 上海京新生物医药有限公司 | 凝血因子XIa抑制剂 |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| WO2022083707A1 (zh) * | 2020-10-23 | 2022-04-28 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物或其盐的医药用途 |
| CN112679446A (zh) * | 2020-10-26 | 2021-04-20 | 都创(上海)医药科技有限公司 | 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法 |
| CN117480164B (zh) * | 2020-12-11 | 2024-07-05 | 上海领泰生物医药科技有限公司 | 凝血因子XIa抑制剂及其制备方法和应用 |
| CN112675173B (zh) * | 2020-12-25 | 2022-04-05 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
| CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN114315623B (zh) * | 2022-01-13 | 2024-02-09 | 上海彤颜实业有限公司 | 一锅合成花椒素wgx-50及其衍生物的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040180855A1 (en) * | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| EP1810965A4 (en) * | 2004-10-13 | 2009-10-28 | Eisai R&D Man Co Ltd | HYDRAZIDE DERIVATIVES |
| US7459564B2 (en) * | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
| CN101316597B (zh) * | 2005-11-03 | 2013-04-17 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
| WO2007070818A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US8466295B2 (en) * | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| CA2633252A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| JP5342450B2 (ja) * | 2006-12-15 | 2013-11-13 | ブリストル−マイヤーズ スクイブ カンパニー | 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ |
| CN101784516B (zh) * | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
-
2009
- 2009-03-12 JP JP2010550858A patent/JP5537442B2/ja not_active Expired - Fee Related
- 2009-03-12 AT AT09720875T patent/ATE543811T1/de active
- 2009-03-12 ES ES09720875T patent/ES2380648T3/es active Active
- 2009-03-12 EP EP09720875A patent/EP2265601B1/en not_active Not-in-force
- 2009-03-12 CN CN200980117506.8A patent/CN102026996B/zh not_active Expired - Fee Related
- 2009-03-12 WO PCT/US2009/036934 patent/WO2009114677A1/en not_active Ceased
- 2009-03-12 US US12/921,177 patent/US8324199B2/en active Active
- 2009-03-13 TW TW098108304A patent/TW200942527A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102026996B (zh) | 2015-01-07 |
| EP2265601A1 (en) | 2010-12-29 |
| ES2380648T3 (es) | 2012-05-17 |
| CN102026996A (zh) | 2011-04-20 |
| EP2265601B1 (en) | 2012-02-01 |
| ATE543811T1 (de) | 2012-02-15 |
| WO2009114677A1 (en) | 2009-09-17 |
| US20110021492A1 (en) | 2011-01-27 |
| JP2011514910A (ja) | 2011-05-12 |
| JP5537442B2 (ja) | 2014-07-02 |
| US8324199B2 (en) | 2012-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200942527A (en) | Pyridazine derivatives as factor XIa inhibitors | |
| PH12012501589A1 (en) | Macrocycles as factor xia inhibitors | |
| MX2015000892A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| MX2015000919A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| PH12021550418A1 (en) | Macrocycles with hetrocyclic p2` groups as factor xia inhibitors | |
| PH12020500195A1 (en) | Pyrimidinones as factor xia inhibitors | |
| TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
| EA201490418A1 (ru) | Новые макроциклические соединения в качестве ингибиторов фактора xia | |
| WO2008075172A3 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| IN2014CN02806A (zh) | ||
| IN2014CN02805A (zh) | ||
| MY150596A (en) | Hsp90 inhibitors | |
| WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
| JO3067B1 (ar) | بيرميدينات بيرازولو امينو كمثبطات ل fak | |
| UA97821C2 (en) | Cyclized derivatives as eg-5 inhibitors | |
| UA99787C2 (en) | Lactams as beta secretase inhibitors | |
| TN2009000178A1 (en) | Substituted pyrazole and triazole compounds as ksp inhibitors | |
| WO2007029062A3 (en) | Novel pyridine derivatives | |
| TN2010000362A1 (en) | Oxim derivatives as hsp90 inhibitors |